|
MRI News Service:
'Ferumoxytol' |
|
|
|
 |
 | | | ''Gadolinium chelates have been used as standard contrast agents for clinical magnetic resonance imaging (MRI) for several decades. However, several investigators recently reported that rare ...' | | Saturday, 5 February 2022 by www.ncbi.nlm.nih.gov |
|
|
|
| | | ''1. Whole-body diffusion-weighted MRI with ferumoxytol had comparable sensitivity and specificity to 18FDG-PET/CT scans in pediatric lymphoproliferative disorder and malignant sarcoma staging. 2. The use of IV ferumoxytol as contrast agent was not ...' | | | Wednesday, 19 February 2014 by www.2minutemedicine.com | |
|
|
|
| | | ''The speed of ferumoxytol uptake on magnetic resonance imaging (MRI) may indicate if a cerebral aneurysm is unstable and likely to rupture soon, say US researchers. This novel MRI technique holds promise for patients harboring unruptured cerebral ...' | | | Friday, 16 November 2012 by www.news-medical.net | |
|
|
|
| | | ''AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the company has updated the product label for Feraheme(R) (ferumoxytol) Injection for Intravenous (IV) use. This update is based on the U.S. Food and Drug Administration's approval of the ...' | | | Tuesday, 21 June 2011 by ir.amagpharma.com | |
|
|
|
| | | ''AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Takeda Pharmaceutical Company Limited (TSE: 4502) today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use. On June 1, 2010, AMAG submitted a ...' | | | Tuesday, 29 June 2010 by www.snl.com | |
|
|
|
| | | ''AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Takeda Pharmaceutical Company Limited (TSE: 4502) today jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme(R) (ferumoxytol) ...' | | | Thursday, 1 April 2010 by www.snl.com | |
|
|
|
| | | ''AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company and provide an update on the commercial launch of Feraheme(R) (ferumoxytol) Injection at the 28th Annual ...' | | | Tuesday, 5 January 2010 by www.snl.com | |
|
|
|
| | | ''The Company commenced the U.S. commercial launch of Feraheme(TM) (ferumoxytol) Injection on July 13, 2009, within two weeks of receipt of FDA approval. The Company reported $3.0 million of total revenues for the third quarter ...' | | | Thursday, 29 October 2009 by www.snl.com | |
|
|
|
| | | ''AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Feraheme(TM) (ferumoxytol) Injection is now available for commercial sale in the United States. Feraheme is an intravenous (IV) iron replacement therapy for the treatment of iron deficiency ...' | | | Monday, 13 July 2009 by www.snl.com | |
|
|
|
| | | ''CAMBRIDGE, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Advanced Magnetics, Inc. today announced that after a recent meeting with the U.S. Food and Drug Administration (FDA) to evaluate its Phase III development program for ferumoxytol in IV iron ...' | | | Thursday, 11 August 2005 by www.biospace.com | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
I'm living so far beyond my income that we may almost be said to be living
apart.
- e e cummings |
|
|
News
top
